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ABSTRACT
Chikungunya virus (CHIKV) is a reemergingmosquito-transmitted alphavirus that causes epidemics of debilitating polyarthritis in
humans. A prior study identified two anti-CHIKVmonoclonal antibodies ([MAbs]CHK-152 andCHK-166) against the E2 andE1
structural proteins, which had therapeutic efficacy in immunocompetent and immunocompromisedmice. CombinationMAb therapy
was required as administration of a singleMAb resulted in the rapid selection of neutralization escape variants and treatment failure in
mice.Here, we initially evaluated the efficacy of combinationMAb therapy in a nonhumanprimatemodel of CHIKV infection. Treat-
ment of rhesusmacaqueswithCHK-152 andCHK-166 reduced viral spread and infection in distant tissue sites and also neutralized
reservoirs of infectious virus. Escape viruseswere not detected in the residual viral RNApresent in tissues and organs of rhesusma-
caques. To evaluate the possible significance ofMAb resistance, we engineered neutralization escape variant viruses (E1-K61T, E2-
D59N, and the doublemutant E1-K61TE2-D59N) that conferred resistance toCHK-152 andCHK-166 and tested them for fitness in
mosquito cells, mammalian cells, mice, andAedes albopictusmosquitoes. In both cell culture andmosquitoes, the mutant viruses
grew equivalently and did not revert to wild-type (WT) sequence. All escape variants showed evidence of mild clinical attenua-
tion, with decreased musculoskeletal disease at early times after infection inWTmice and a prolonged survival time in immuno-
compromised Ifnar1/mice. Unexpectedly, this was not associated with decreased infectivity, and consensus sequencing from
tissues revealed no evidence of reversion or compensatory mutations. Competition studies with CHIKVWT also revealed no
fitness compromise of the double mutant (E1-K61T E2-D59N) neutralization escape variant inWTmice. Collectively, our study
suggests that neutralization escape viruses selected during combinationMAb therapy with CHK-152 plus CHK-166 retain fit-
ness, cause less severe clinical disease, and likely would not be purified during the enzootic cycle.
IMPORTANCE
Chikungunya virus (CHIKV) causes explosive epidemics of acute and chronic arthritis in humans inAfrica, the Indian subcontinent,
and Southeast Asia and recently has spread to theNewWorld. As there are no approved vaccines or therapies for humanuse, the possi-
bility of CHIKV-induced debilitating disease is high inmany parts of theworld. To this end, our laboratory recently generated a com-
binationmonoclonal antibody therapy that aborted lethal and arthritogenic disease inwild-type and immunocompromisedmice
when administered as a single dose several days after infection. In this study, we show the efficacy of the antibody combination in non-
humanprimates and also evaluate the significance of possible neutralization escapemutations inmosquito andmammalian cells,
mice, andAedes albopictus vector mosquitoes. Our experiments show that escape viruses from combination antibody therapy
cause less severe CHIKV clinical disease, retain fitness, and likely would not be purified by mosquito vectors.
Although chikungunya virus (CHIKV)was first isolated from afebrile patient with severe joint pain in Tanzania in 1953 (1),
it is believed that the virus has caused disease in Africa and South-
east Asia since the late 1700s (2). Historically, CHIKV infection
caused periodic, contained outbreaks across Africa and Asia (2).
Between 2005 and 2007, however, an explosive epidemic of
CHIKV infection of unprecedented magnitude occurred; it initi-
ated on the coast of Kenya in 2004, from which it dispersed to the
French island of La Reunion, other Indian Ocean islands, and
many nations in Africa and Asia (2–4). The recent CHIKV epi-
demic has affected over 5 million people, including one-third of
the population (300,000 people) of La Reunion Island (4, 5).
Although travelers returning from countries of endemicity to
Canada, Europe, and the United States have acquired CHIKV in-
fection anddisease, local epidemics in the developedworld did not
occur until 2007, with the onset of the first European outbreak,
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which caused 229 cases and one fatality in Northern Italy (6, 7). In
2010, cases of CHIKV infection also were reported in France (8).
Most recently, in 2013 and 2014, local epidemics of CHIKV infec-
tion were reported in the Americas in several countries in the
Caribbean, providing the first evidence of autochthonous trans-
mission in theNewWorld (http://www.cdc.gov/chikungunya/geo
/americas.html).
CHIKV is transmitted by the Aedes species mosquitoes and is
maintained in a sylvatic cycle in Africa, where nonhuman pri-
mates and rodents are reservoirs and where forest-dwelling mos-
quitoes (chiefly theAedes species furcier, taylori, luteocephalus, and
africanus) are vectors for transmission (9, 10). During epidemics,
humans serve as the principal reservoirs. Aedes aegypti, an urban
mosquito that maintains close association with humans, is the
primary vector in Asia. Aedes albopictus was the vector primarily
responsible for the La Reunion epidemic in 2005 to 2007 due to a
single amino acid mutation that enhanced vector infectivity and
epidemic potential (11). A. albopictus mosquitoes have spread to
include all continents, tropical and temperate (12), so CHIKV
epidemics could occur anywhere (13). The changing epidemiol-
ogy of CHIKV and ubiquity of its mosquito vectors highlight the
likelihood of its continued global spread.
Acute CHIKV infection manifests 3 to 7 days after inoculation
by an Aedes mosquito bite. Symptoms include an abrupt onset of
a high fever, rash, polyarthralgia, and myalgia (14, 15). Polyar-
thralgia is mainly symmetric and tends to occur in previously
injured or distal joints (16). Acute symptoms persist for about 14
days, but chronic arthralgia can linger and cause morbidity for
weeks or even years. Tenosynovitis is observed commonly in the
chronic, recurring form of CHIKV disease and often affects the
wrists, fingers, and ankles (17). Joint pain can be debilitating; a
recent study showed that severe arthralgia persisted for at least 36
months in60% of a cohort of CHIKV-infected patients (18).
The CHIKV genome is an 11.8-kb single-stranded, positive-
sense RNA with two open reading frames (ORFs). It is one of 29
alphaviruses and belongs to the Togaviridae family of enveloped
viruses. There are three genotypes of CHIKV: East/Central/South
African (ECSA), Asian, andWest African, which are between 95.2
and 99.8% identical at the amino acid level (19, 20). The CHIKV
genome is flanked by untranslated regions with a 5= N-methyl
guanosine cap and poly(A) tail, between which the two ORFs re-
side. The 5= two-thirds of the genome encodes four nonstructural
proteins (nsP1, -2, -3, and -4). The second ORF, which is down-
stream of a separate 26S subgenomic promoter (21), encodes the
structural proteins: C (nucleocapsid protein), E3, E2, 6K, TF, and
E1. The mature virion is comprised of the nucleocapsid protein C
and two glycoproteins, E1 and E2, with E2 functioning in attach-
ment to cells and E1 participating in virus fusion. Each 700-Å
CHIKV virion contains 240 copies of the envelope and capsid
proteins, which are arranged in T4 quasi-icosahedral symmetry.
E1-E2 heterodimers assemble into 80 trimeric spikes on the virus
surface (22). X-ray crystallographic structures (23–26) have elu-
cidated the architecture of the glycoprotein shell. The E1 ectodo-
main consists of three domains. Domain I (DI) lies between DII
and DIII, the latter of which adopts an immunoglobulin-like fold.
The fusionpeptide is located at the distal end ofDII. E1monomers
sit at the base of the surface spikes and form a trimer around each
of the icosahedral axes. E2 localizes to a long, thin, leaf-like struc-
ture on the top of the spike and contains three domains with
immunoglobulin-like folds: the N-terminal domain A, located at
the center; domain B at the tip; and the C-terminal domain C,
located proximal to the viral membrane.
CHIKV infection in vivo has been studied extensively in mice
(27–35). Newborn outbred mice exhibit gait instability, lethargy,
and weight loss after CHIKV infection (27). Neonatal inbred
C57BL/6 mice are vulnerable to fatal CHIKV infection; viral rep-
lication in these animals is observed in muscle, joint, skin, and
brain (28). Adult mice with defective type I interferon (IFN) sig-
naling (Ifnar1/ mice) develop lethal infection, with muscle,
joint, and skin serving as primary sites of replication (28, 34).
CHIKV infection in 2- to 6-week-old wild-type (WT) inbred
C57BL/6 and outbred CD-1 mice results in rheumatologic and
musculoskeletal disease (29, 30, 36) that mimics human illness in
some respects and can progress to persistent infection (31). In-
fected mice develop metatarsal foot swelling with histological ev-
idence of arthritis, tenosynovitis, and myositis. In cynomolgus
macaques, CHIKV persists in joints, muscles, lymphoid organs,
and liver for at least 3 months (37), providing a possible explana-
tion for the long-lasting CHIKV symptoms observed in humans.
While adult rhesusmacaques effectively control CHIKV infection,
aged animals developed persistent infection in the spleen (38).
The importance of the humoral response in preventing or con-
trolling CHIKV infection has been established (39). Immune
gamma globulin fromdonors in the convalescent phase of CHIKV
infection displays strong neutralizing activity in vitro and protec-
tive efficacy in Ifnar1/ and neonatal WT mice (28). E1- or E2-
specific monoclonal antibodies (MAbs) or immune sera exhibit
protective efficacy in vivo against other alphaviruses (40–48). Pro-
tective human and mouse MAbs against CHIKV E2 protein that
bind domain B, domain A, or the fusion loop groove neutralize
CHIKV infection and prevent or mitigate disease in vivo (49–55).
Anti-E1MAbs against CHIKVwith protective activity inmice also
have been described (52).
Recently, we identified several neutralizing anti-CHIKVMAbs
that provided complete protection against lethality as prophylaxis
in highly susceptible Ifnar1/ mice (52). Our two most protec-
tive MAbs (CHK-152 and CHK-166) mapped to distinct epitopes
on the E2 and E1 structural proteins. In postexposure therapeutic
trials, a single dose of a combination of the two MAbs (CHK-152
plus CHK-166) limited the development of resistance and pro-
tected Ifnar1/mice against disease when it was administered 24
to 36 h before CHIKV-induced death. Here, we evaluated the
efficacy of combinationMAb therapy against CHIKV infection in
rhesus macaques and the significance of possible resistance in
mosquito and mammalian cells, immunocompetent and immu-
nocompromised mice, and A. albopictus mosquitoes.
MATERIALS AND METHODS
Ethics statement. All rhesus macaques were handled in accordance with
good animal practice as defined by the relevant national and/or local
animal welfare bodies. Infection studies with rhesus macaques were ap-
proved by the OregonNational Primate Research Center (ONPRC) Insti-
tutional Animal Care and Use Committee, which is accredited by the
Assessment and Accreditation of Laboratory Animal Care International.
For blood collection, monkeys were anesthetized with ketamine by intra-
muscular injection. Euthanasia was conducted under anesthesia with ket-
amine, followed by an overdose of sodium pentobarbital, as recom-
mended by the American Veterinary Medical Association. Experiments
with Ifnar1/mice were performed according to the guidelines andwith
the approval of theWashington University Institutional Animal Care and
Use Committee. Experiments withWT C57BL/6 mice were performed in
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accordance and with approval of the University of Colorado School of
Medicine Institutional Animal Care andUseCommittee guidelines. Foot-
pad injections were performed under anesthesia that was induced and
maintained with ketamine hydrochloride and xylazine or isoflurane, and
all efforts were made to minimize suffering.
Cells and viruses. Vero and BHK21 cells were cultured in Dulbecco’s
modified Eagle medium (DMEM) supplemented with 5% and 10% fetal
bovine serum (FBS; Omega Scientific), respectively, 10mMHEPES, non-
essential amino acids (Cellgro), and antibiotics (penicillin and streptomy-
cin) at 37°C in a 5% CO2 incubator. C6/36 A. albopictus cells were culti-
vated in Leibovitz-15medium (Invitrogen) supplemented with 10% FBS,
10mMHEPES, and antibiotics (penicillin and streptomycin) at 27°C. The
infectious clone of CHIKV LR 2006 OPY-1 (CHIKV-LR) has been de-
scribed previously (56). The CHIKV pDonor221 plasmid containing the
WT or mutated structural genes was published previously (52) and was
provided by K. Dowd and T. Pierson (Bethesda, MD). Single point mu-
tations (E1-K61T or E2-D59N) were introduced into the infectious clone
after QuikChange site-directed mutagenesis (Agilent Technologies)
(primers are listed in Table S1 in the supplementalmaterial) by ligating an
SgrA1 and SfiI (New England BioLabs) doubly digested pDonor221 frag-
ment. The double mutant E1-K61T E2-D59N was created by performing
sequential mutagenesis reactions. All WT and mutant infectious clones
were sequenced in their entirety.
To produce recombinant virus from infectious cDNA clones, plas-
mids were linearized with the restriction endonuclease NotI (New Eng-
land BioLabs), and N7-methyl-guanosine-capped RNA was produced in
vitro using an SP6 DNA-dependent RNA polymerase transcription kit
according to the manufacturer’s instructions (mMessage kit; Ambion).
CHIKV RNAwas electroporated with three pulses at 850 V, with 25F of
capacitance and infinite resistance in a 2-mm cuvette into BHK21 cells.
The supernatant was harvested 28 h later, aliquoted, and stored frozen at
80°C to generate the passage 0 (P0) stock. C6/36 cells were infected with
the P0 CHIKV-LR at a multiplicity of infection (MOI) of 0.01, in the
presence of 10 g/ml of either CHK-166 (for CHIKV E1-K61T), CHK-
152 (for CHIKV E2-D59N) and 10 g/ml of CHK-166 and CHK-152
(CHIKV E1-K61T E2-D59N). Supernatant was harvested 68 to 72 h later.
Virus titers were determined on Vero cells by focus-forming unit (FFU)
assay. Virus from insect or mammalian cell stocks was sequenced to con-
firm retention of the mutated amino acids.
Virus titration assays. Vero cells (seeded overnight at 3  104 cells/
well, in 96-well plates) inDMEMwith 5%FBSwere infected at 37°C for 90
min with serial dilutions of virus stocks and then overlaid with 1% (wt/
vol) methylcellulose in modified Eagle medium (MEM) supplemented
with 4% FBS. Plates were harvested 18 h later and fixed with 1% (wt/vol)
paraformaldehyde in phosphate-buffered saline (PBS). The plates were
incubated sequentially with 500 ng/ml of a chimeric mouse-human anti-
CHIKV MAb (ch-CHK-9) as described previously (52) and a 0.3 g/ml
solution of horseradish peroxidase (HRP)-conjugated goat anti-human
IgG secondary antibody (Sigma) in PBS supplementedwith 0.1% saponin
and 0.1% bovine serum albumin (BSA). CHIKV-infected foci were visu-
alized using TrueBlue peroxidase substrate (KPL) and quantitated on an
ImmunoSpot, version 5.0.37, macroanalyzer (Cellular Technologies,
Ltd.).
Viral growth curves. Vero cells were seeded overnight at 6  104
cells/well in 12-well plates in 1 ml of DMEM containing 5% FBS. C6/36
cell-derived CHIKV (WT or mutant) was incubated with 10 g/ml of
CHK-166, CHK-152, both CHK-166 and CHK-152, or noMAb for 1 h at
37°C. Medium was removed from Vero cells, and virus-MAb complexes
in 500 l were added for 1 h at 37°C. Subsequently, the inoculum was
removed, and cells were rinsed with PBS. Medium containing the respec-
tive MAb or no MAb was added back to the cells. Cells were harvested at
time points 1, 12, 24, and 36 h postinfection. Analogously, growth curves
were performed on C6/36 cells with P0 BHK-derived CHIKV (WT and
mutant), and cells were harvested at time points 1, 24, 48, and 72 h postin-
fection. Virus titers were determined by focus-forming assay as described
above.
Mouse experiments. Ifnar1/ mice were obtained from J. Sprent
(Scripps Institute, San Diego, CA) and backcrossed 10 times onto the
C57BL/6 background.Rag1/micewere purchased commercially (Jack-
son Laboratories). Ifnar1/ and Rag1/ mice were bred in the patho-
gen-free animal facilities of Washington University School of Medicine.
Someof the 6- to 8-week-old Ifnar/micewere treated at day1with 50
g of CHK-152 and CHK-166 by intraperitoneal (i.p.) injection. Other
Ifnar1/ or Rag1/ mice received the WT and mutant viruses in the
absence of MAb pretreatment. Ifnar1/ or Rag1/ mice were inocu-
lated subcutaneously in the footpad with 10 FFU or 103 FFU, respectively,
of C6/36 cell-derived CHIKV-LR (WT, E1-K61T, E2-D59N, or E1-K61T
E2-D59N) in 50l of Hanks balanced salt solution (HBSS) supplemented
with 1% heat-inactivated FBS.
C57BL/6 WT mice were obtained from the Jackson Laboratory and
bred in specific-pathogen-free facilities at the University of Colorado.
Three-week-old mice were used for all of these studies. Mice were inocu-
lated in the left rear footpadwith 103 FFUofCHIKV (WT,mutant viruses,
or a defined mixture of WT and mutant viruses) in PBS supplemented
with 1% FBS in a volume of 10 l. Mice were monitored for disease signs
andweighed at 24-h intervals.On the termination day of each experiment,
mice were sedated with isoflurane and euthanized by thoracotomy and
exsanguination. Mice were perfused by intracardiac injection with PBS,
and tissues were removed by dissection and homogenized in TRIzol re-
agent (Life Technologies) for RNA isolation.
Nonhuman primate experiments.Adult male and female rhesus ma-
caques (ranging from 6 to 13 years old) were infected subcutaneously in
both arms with 107 PFU of the CHIKV-LR strain in 1ml of PBS. At days 1
and 3 postinfection, animals were injected intravenously (n 6 per group
in two independent experiments)with a total of 15mg/kg ofMAbs against
CHIKV E1 and E2 (mixture of MAb CHK-152 and CHK-166) or West
Nile virus (WNV) E (WNV E16, negative control) while under sedation.
MAbs were diluted in approximately 15 to 20 ml of saline solution for a
total volume of 25 ml. Blood samples were obtained following ketamine
sedation (10 mg/kg) on the day of infection (day 0) and at days 1, 2, 3, 4,
5, and 7 postinfection. Peripheral blood mononuclear cells (PBMC) were
isolated from whole blood by centrifugation over Histopaque gradient
(Sigma-Aldrich). Animals were euthanized at 7 days postinfection (dpi).
At the time of harvest, organs, lymphoid tissues, joints, and muscles were
collected and processed for nucleic acid detection and plaque assays to
quantify levels of CHIKV.
qRT-PCR analysis for CHIKV. (i) Rhesusmacaques.Viral RNA load
in the tissues at necropsy of the rhesus macaques was quantified using
real-time reverse transcription-PCR (RT-PCR) (38). Primers and probes
included the following: CHIKV-9482F, 5=-GGAACGAGCAGCAACCTT
TG-3=; CHIKV-9931R, 5=-ATGGTAAGAGTCTCAGACAGTTGCA-3=;
and the TaqMan probe CHIKV-9870F, 5=-GGAATAAGGGCTTGT-3=.
Total RNAwas prepared from tissue specimens using TRIzol according to
the manufacturer’s instructions (Life Technologies). The isolated RNA
was quantified using a Nanodrop spectrophotometer. RNA was treated
with RNase-free DNase, and then single-stranded cDNA was generated
using random hexamers and Superscript III RT (Invitrogen, Carlsbad,
CA). Gene amplicons served as quantification standards (sensitivity, 10 to
100 copies). Quantitative RT-PCR (qRT-PCR) was performed and ana-
lyzed usingABI StepOne Plus real-time PCR system (Applied Biosystems)
as described previously (31).
(ii)Mice.RNAwas isolated using a PureLink RNAminikit (Life Tech-
nologies), and the amount of CHIKV positive-strand RNA present in
tissues was quantified by qRT-PCR as previously described (31). Briefly,
the first-strand cDNA reaction was primed with 250 ng of random prim-
ers (Life Technologies). A CHIKV sequence-specific forward primer
(CHIKV-2411F, 5=-AGAGACCAGTCGACGTGTTGTAC-3=) and re-
verse primer (CHIKV-2676R, 5=-GTGCGCATTTTGCCTTCGTA-3=)
were used in conjunction with a TaqMan probe (CHIKV-2579F, 5=-ATC
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TGCACCCAAGTGTACCA-3=). For absolute quantification of CHIKV
RNA, a standard curve was generated: 10-fold dilutions from 108 to 100
copies of CHIKVpositive-strand genomic RNA, synthesized in vitro, were
spiked into RNA from BHK-21 cells, and reverse transcription and quan-
titative PCR (qPCR)were performed in an identicalmanner. No template
controls were run in parallel.
Quantitative analysis for infectious CHIKV. Infectious viral load
from tissues was determined by limiting-dilution plaque or focus-form-
ing assay. Tissues were homogenized using a bead beater (Precellys 24
homogenizer), and cellular debris was pelleted by centrifugation (5,000
g for 2min). The titer of a 100-l sample of the clarified tissue supernatant
or blood plasma was determined on Vero or BHK21 cells. The genome-
to-FFU ratios of stockWT andmutated viruses were determined bymea-
suring the number of viral RNA copies per FFU using a standard curve
and quantitative RT-PCR.
Mosquito infection experiments. A. albopictus mosquitoes (La Re-
union strain) were reared according to standard procedures. Adult fe-
males were fed amixture of defibrinated sheep blood and P0 stocks ofWT
or CHIKV mutants (E1-K61T, E2-D59N, and E1-K61T E2-D59N) that
were generated in BHK21 cells in a 1:1 blood/culture supernatant ratio.
The titers of theWT, E1 K61Tmutant, E2 D59Nmutant, and E1 K61T E2
D59N double mutant were, respectively, 7.56, 7.36, 7.59, and 7.49 log10
tissue culture infectious dose 50% endpoint titers (TCID50)/ml. After
feeding, mosquitoes were anesthetized, and engorged females were sepa-
rated into cartons and held for a 14-day extrinsic incubation period at
28°C, 70 to 80% relative humidity, and a 16:8 photoperiod. In separate
experiments, mosquitoes were fed a blood meal using the same virus
stocks and harvestedwithin 1 h of feeding.Mosquitoes were collected at 7,
10, and 14 days postinfection and titrated to determine viral titer of ab-
domens containing the midguts with surrounding tissues or secondary
tissues, including heads, wings, and legs for dissemination, or used for
RNA extraction and sequencing. Viral titers frommosquito samples were
determined using Vero cells and expressed as log10 TCID50/ml as previ-
ously described (11).
ViralRNAsequencing fromcells and tissues. (i)Cell culture.Veroor
C6/36 cells were infected withWT or CHIKVmutants as described above.
Cell supernatants were collected at 36 or 72 h after infection, respectively,
and RNA was isolated using a QIAamp viral RNA minikit (Qiagen).
cDNA was produced using a Superscript III First Strand System (Life
Technologies). Phusion DNA polymerase (New England BioLabs) was
used to produce a PCR amplicon spanning the E2-E1 structural genes.
Amplicons were purified by agarose gel electrophoresis, sequenced using
overlapping primers (see Table S1 in the supplemental material), and
analyzed using Geneious software.
(ii) Mouse tissues. Tissues were perfused extensively with PBS and
then removed by dissection and homogenized in TRIzol reagent (Life
Technologies). Total RNA was isolated from the right ankle using a
PureLink RNA kit (Life Technologies). The first-strand cDNA reaction
was primed with 250 ng of random primers. PCRs were performed with a
set of overlapping primers that amplified the complete E2 and E1 coding
regions (see Table S1 in the supplemental material). Amplicons were pu-
rified by agarose gel electrophoresis and sequenced directly on a fluores-
cent capillary automated sequencer at the University of Colorado DNA
sequencing and analysis core. Sequence alignments were performed using
Geneious Pro software.
(iii) Mosquitoes.Whole mosquito bodies were collected and homog-
enized in RLT lysis buffer, and RNA was extracted using RNeasy kits
(Qiagen). Samples were screened for CHIKV infection using a OneStep
RT-PCR kit (Qiagen), and primers that amplified the complete E2-E1
genes were used for sequencing (see Table S1).
(iv) Nonhuman primates. Rhesus macaque joint and organ tissues
were homogenized in 1ml of TRIzol reagent plus approximately 250l of
SiLiBeads, type S (1.7 to 2.1 mm; VWR), using a Precellys 24 homoge-
nizer. Total RNA was isolated according to the manufacturer’s specifica-
tions, and first-strand cDNA was synthesized using a 10 M oligonucle-
otide mix consisting of random primers and oligo(dT). PCRs were
performedwith AmpliTaq Gold 360 (Invitrogen) and primers adjacent to
E1 and E2 (see Table S1 in the supplemental material). Amplicons were
cloned into the pGEM Teasy vector (Promega), transformed in bacteria,
and expanded overnight in LB medium. Plasmids were purified using a
Genelute Plasmid Mini Prep kit (Sigma), and sequencing was performed
by the ONPRC Sequencing Core using a fluorescent capillary automated
sequencer.
Cytokine bioplex assay. WT mice were inoculated with 103 FFU of
CHIKV WT or CHIKV E1-K61T E2-D59N virus; at day 3 after infection
blood was collected, and serum was isolated. A BioPlex Pro assay was
performed according to the manufacturer’s protocol (Bio-Rad). The cy-
tokine screen included interleukin 1 (IL-1), IL-1, IL-2, IL-3 IL-4,
IL-5, IL-6, IL-9, IL-10, IL-12 p40, IL-12 p70, IL-13, IL-17, granulocyte
colony-stimulating factor (G-CSF), granulocyte-macrophage colony-
stimulating factor (GM-CSF), gamma interferon (IFN-	), monocyte che-
motactic protein 1 (MCP-1), macrophage inflammatory protein 1
(MIP-1), MIP-1, RANTES, and tumor necrosis factor alpha (TNF-).
Statistical analysis. All data were analyzed using Prism software
(GraphPad software). For survival analysis, Kaplan-Meier survival curves
were analyzed by log rank test. For growth kinetics and neutralization, an
unpaired t test or analysis of variance (ANOVA) was used to determine
statistical significance. AMann-Whitney test was used to analyze cytokine
and chemokine levels in serum.
RESULTS
Anti-CHIKV MAb therapy reduces viral spread in nonhuman
primates. A prior study established the therapeutic efficacy of a
combination of two MAbs (CHK-152 and CHK-166) against
CHIKV infection in mice (52). As a next step toward evaluating
the possible utility of this approach in humans, we assessed the
efficacy of combinationMAb therapy in nonhuman primates, us-
ing a recently developed rhesus macaque model of CHIKV infec-
tion (38). We infected adult rhesus macaques subcutaneously in
both arms with 107 PFU of the epidemic CHIKV-LR strain. On
days 1 and 3 postinfection, the infected animalswere administered
mouse MAbs (15 mg/kg, intravenously) directed against CHIKV
E2 and E1 (CHK-152 and CHK-166) or, as a negative control,
against WNV E protein (WNV E16). Blood was collected at day 0
immediately prior to infection, on days 1, 2, 3, 4, and 5 after
infection, and at necropsy on day 7. Plasma mouse MAb concen-
trations were determined by enzyme-linked immunosorbent as-
say (ELISA) (Fig. 1A); similar peak levels were observed for both
treatment groups, with the highest levels following the second
injection. Combination MAb therapy completely neutralized in-
fectious CHIKV in blood compared to animals treated with the
control anti-WNVMAb (Fig. 1B). CHIKV RNA loads in the arm
joints (finger, wrist, and elbow) and muscles (biceps, triceps, and
brachial radius) were similar for both treatments, suggesting that
by 1 day after infection the virus established infection in these
tissues. However, combination anti-CHIKV MAb treatment re-
duced viral burden in the joints andmuscles of the legs, indicating
that therapy reduced viral dissemination, as follows: knee, 270-
fold (P
 0.003); ankle, 114-fold (P
 0.002); toes, 62-fold (P

0.0006); soleus, 78-fold (P
 0.05); and hamstring (semitendino-
sus and semimembranosus), 3-fold (P 
 0.05) muscles (Fig. 2A
and B). Analogously, viral burdens in the axillary lymph nodes
were similar after anti-CHIKV or control MAb treatment (Fig.
2C) but were lower in the anti-CHIKV MAb-treated animals in
the mesenteric (27-fold lower; P
 0.009) and inguinal (287-fold
lower; P 
 0.003) lymph nodes, which drain the gut and legs,
respectively. While trends were present, anti-CHIKV therapy did
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not reduce the viral load in the lung or kidney in a statistically
significant manner. Although infectious CHIKV was isolated
from tissues from all of the control MAb-treated animals, we
failed to detect any infectious virus in harvested tissues from rhe-
sus macaques treated with anti-CHIKV MAbs (data not shown),
despite the presence of viral RNA. Consensus sequencing of the
remaining viral RNA in tissues at day 7 failed to reveal any amino
acid changes in the E1 or E2 gene (see Fig. S1 in the supplemental
material). These findings indicate that within 24 h of inoculation
in rhesus macaques, CHIKV has established itself within tissues
near the site of infection and the adjacent draining lymph nodes.
Combination therapy with anti-CHIKVMAbs reduced viral load
at distant sites of infection, neutralized the existing reservoir of
infectious virus, and limited the development of resistance.
Stability of neutralization escape variants in mosquito and
mammalian cells. As part of prior epitope mapping studies, we
identified neutralization escape variants in cell culture and in vivo
against CHK-152 andCHK-166 (52). E2-D59Nwas the dominant
amino acid mutant selected under immune pressure from CHK-
152 both in vivo and in cell culture. Analogously, an E1-K61T
mutation consistently was selected in the presence of CHK-166 in
cell culture. To understand the significance of these mutations in
the context of combination MAb therapy, we engineered E2-
D59N, E1-K61T, and E2-D59N E1-K61T mutations into the in-
FIG1 Anti-CHIKV therapy reduces viremia in rhesusmacaques. Rhesusmacaqueswere infectedwith 107 PFUofCHIKV-LR and injected intravenously at 1 and
3 dpi with anti-CHIKV antibodies or a control WNVMAb (15 mg/kg). At 0, 1, 2, 3, 4, 5, and 7 dpi, peripheral blood samples were collected and processed for
plasma. (A) Plasma anti-CHIKV mouse MAb titers were measured by ELISA (n 3/group). The numbers under each treatment refer to the individual rhesus
macaques used in this study. (B) Levels of CHIKV in plasma weremeasured by limiting-dilution plaque assay. Antibodies directed against CHIKV but notWNV
lowered viremia to undetectable levels at 2 dpi, and this effect was maintained until the study endpoint (7 dpi) (n  3 per group; P 
 0.01 at 2 dpi, two-way
ANOVA).
FIG 2 Anti-CHIKV therapy reduces CHIKV dissemination in rhesus macaques. Rhesus macaques were treated at 1 and 3 dpi with anti-CHIKV antibodies or
control anti-WNV antibody (15mg/kg). Necropsy occurred at 7 dpi, andmonkey tissue samples were processed for total RNA by the TRIzol method (n 6 per
group). Quantitative RT-PCR was used to detect CHIKV loads in joints, muscle, and other organs and lymph nodes. Virus dissemination to peripheral muscles
and joints (leg), organs (lung and kidney), and lymphnodes ([LN] inguinal andmesenteric) was greatly reduced by anti-CHIKV treatment. Viral loads in the arm
muscles and joints (site of infection) as well as spleen and draining lymph nodes (axillary) were not affected by the antibody treatment. Asterisks indicate
statistically significant differences (*, P
 0.05; **, P
 0.01; ***, P
 0.001) as judged by a Mann-Whitney test.
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fectious cDNA clone of CHIKV (strain LR 2006 OPY-1), gener-
ated the recombinant viruses, and tested them for growth in insect
and mammalian cells in the presence or absence of individual or
combinations of neutralizing MAbs. We hypothesized that indi-
vidual or combinations of mutations might be attenuating and,
thus, revert to WT sequences in the absence of antibody pressure.
Initial studies were performed in C6/36 A. albopictus cells. As ex-
pected, CHIKVWT grew efficiently in C6/36 cells, reaching titers
in the supernatant of108 to 109 FFU/ml by 72 h. Infectious levels
of CHIKV WT were reduced markedly in the supernatants of
C6/36 cells that were pretreated with 10 g/ml of CHK-152 or
CHK-166 (Fig. 3A). CHIKV E1-K61T, CHIKV E2-D59N, and
CHIKV E1-K61T E2-D59N viruses all grew similarly in C6/36
cells, regardless of whether the corresponding neutralizing MAb
(CHK-166, CHK-152, or both) was included (Fig. 3B to D). No
growth defect of any of themutants was observed compared to the
parent CHIKV WT virus in the absence of MAbs (e.g., titers in
FFU/ml at 72 h: WT, 3.3  108; E1-K61T, 2.7  108; E2-D59N,
3.3 108; E1-K61T E2-D59N, 3.4 108). This suggested that the
individual or combinationmutants did not have a fitness defect in
C6/36 cells. To confirm this, we sequenced the E1 and E2 genes of
the virus harvested at the end of the growth curves (72-h time
point) of CHIKV WT, E1-K61T, E2-D59N, and E1-K61T E2-
D59N viruses performed in the absence of MAb treatment. At the
level of consensus sequencing, allmutationsweremaintained, and
no reversion to WT virus was apparent (see Fig. S2 in the supple-
mental material).
We repeated these studies in primate Vero cells, with the idea
that individual or combinations of mutations could impact entry,
assembly, or replication in a different host species. As anticipated,
CHIKV WT grew efficiently in Vero cells, reaching titers in the
supernatant of 107 FFU/ml by 36 h. In comparison, markedly
reduced or no infectious WT virus was observed in Vero cell su-
pernatants that contained 10 g/ml of CHK-166 or CHK-152,
FIG 3 Growth kinetics of WT and mutant CHIKV in insect and mammalian cells. (A to D) C6/36 A. albopictus cells were infected with P0 BHK cell-derived
CHIKVWT (A), CHIKV E1-K61T (B), CHIKV E2-D59N (C), or CHIKV E1-K61T E2-D59N (D) virus. For some experiments, CHIKVs (WT or mutants) were
preincubated with 10 g/ml of CHK-166, CHK-152, or both CHK-166 and CHK-152 for 1 h at 37°C, as indicated. Virus or virus-MAb complexes were added
to C6/36 cells for 1 h at 37°C. After samples were washed to remove free virus and antibody, supernatants were harvested at 1, 24, 48, and 72 h postinfection for
titration by FFU assay. The results are the average of three independent experiments performed in triplicate. Statistically significant differences are indicated (*,
P
 0.05; **, P
 0.01, ***, P
 0.001). For the mutant viruses, none of the differences with and without MAb treatment were significantly different. (E to H)
African green monkey Vero cells were infected with P0 C6/36 cell-derived CHIKV WT (E), CHIKV E1-K61T (F), CHIKV E2-D59N (G), or CHIKV E1-K61T
E2-D59N (H) virus. For some experiments, CHIKVs (WT or mutants) were preincubated with 10 g/ml of CHK-166, CHK-152, or both CHK-166 and
CHK-152 for 1 h at 37°C, as indicated. Virus or virus-MAb complexes were added to Vero cells for 1 h at 37°C. After samples were washed to remove free virus
and antibody, supernatants were harvested at 1, 12, 24, and 36 h postinfection for titration by FFU assay. The results are the average of three independent
experiments performed in triplicate. Statistically significant differences are indicated (*, P
 0.05; **, P
 0.01, ***, P
 0.001). For the mutant viruses, none of
the differences with and without MAb treatment were significantly different.
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respectively (Fig. 3E). The CHIKVE1-K61T and E2-D59N viruses
grew equivalently in the presence or absence of CHK-166 and
CHK-152 (Fig. 3F andG); this suggested that thesemutant viruses
did not have a fitness defect in Vero cells. Similar growth kinetics
were observed with the double mutant (E1-K61T E2-D59N) virus
in the presence or absence of the combination of MAbs (Fig. 3H).
Consistent with the absence of attenuation in Vero cells, sequenc-
ing studies of viruses propagated in the absence ofMAb treatment
confirmed that all mutations were maintained at the 36-h time
point as no reversion to WT virus was present (see Fig. S3 in the
supplemental material). These studies could not be extended fur-
ther in time due to the cytopathic effect of CHIKV inmammalian
cells.
Phenotype of neutralization escape variants in mosquitoes.
Although a growthdefect of the neutralization escapemutantswas
not observed in C6/36 insect cells, infectivity and dissemination in
the A. albopictus vector might differ because of additional cellular
and immune barriers. To evaluate this, live mosquitoes were fed
bloodmeals of CHIKVWT, CHIKV E1-K61T, CHIKV E2-D59N,
or CHIKV E1-K61T E2-D59N virus. In these studies, we used a
relatively high virus dose (107 TCID50 per blood meal) to ensure
optimal infection rates of themosquitoes. At days 7, 10, and 14 the
abdomens and secondary tissues were harvested to determine the
rates of infection and dissemination and the quantity of infectious
viruses. In general, infectivity levels of theWT andmutant viruses
were similar in the abdomens ofA. albopictusmosquitoes over the
first 2 weeks (Table 1). Dissemination also was equivalent as 100%
of the secondary tissues were infected with CHIKV WT, CHIKV
E1-K61T, CHIKV E2-D59N, or CHIKV E1-K61T E2-D59N at
days 7, 10, and 14, with the exception of one nondisseminated
infection with the E2-D59Nmutant at day 7 (Table 2). No differ-
ences were observed among the four CHIKV strains in the mean
infectious titers of whole-mosquito homogenates at day 14
postinfection (Table 1). Sequencing studies of the E2-E1 genes
harvested from whole-mosquito homogenates at day 14 after in-
fection with themutant CHIKV revealed no evidence of reversion
to WT virus despite multiple rounds of replication in the mos-
quito tissues (see Fig. S4 in the supplemental material). Thus, and
similar to the results seen in C6/36 cells in culture, the neutraliza-
tion escape variants showed no evidence of restricted tropism or
altered virulence in vivo in the vector host.
Phenotype of neutralization escape variants during acute in-
fection of immunocompromised mice. Although no growth de-
fects of the mutant viruses were observed in cell culture and mos-
quitoes, these replication dynamics might not reliably predict
phenotypes in mammals due to differences in tropism and im-
mune responses. Initially, we confirmed that preadministration of
a combination (50g each) of CHK-152 andCHK-166 prevented
CHIKV WT-induced lethality in highly vulnerable 6- to 8-week-
old Ifnar1/mice. In the absence of MAbs, all mice succumbed
rapidly to infection with 10 FFU of CHIKV WT, with a mean
survival time of 3.8 0.1 days, similar to that reported previously
(28, 52, 57). In the presence of CHK-152 and CHK-166, as ex-
pected, the Ifnar1/mice failed to develop disease and survived
infection (Fig. 4A and Table 3). Moreover, no viral RNA was re-
covered at day 3 from muscle of CHIKV WT-infected Ifnar1/
mice pretreatedwithCHK-152 andCHK-166, which suggests that
sterilizing immunity was achieved (data not shown).
Parallel infection experiments using analogously passaged (P0)
stocks of CHIKV E1-K61T, CHIKV E2-D59N, or CHIKV E1-
K61T E2-D59N virus revealed a slightly protracted mean survival
time compared to infection with CHIKV WT (WT, 3.8 days; E1-
K61T, 4.9 days; E2-D59N, 4.9 days; and E1-K61T E2-D59N, 5.4
days; P
 0.0001 for all mutants compared to theWT), suggesting
that in vivo the engineered neutralization escape viruses were
slightly attenuated (Fig. 4B to D and Table 3) yet still pathogenic.
As it remained possible that the delay in lethality in Ifnar1/mice
was associated with reversion in the absence of immune pressure,
infection experiments were repeated in the presence of the respec-
tive neutralizing MAb(s). In each case, the mean survival time in
the presence of neutralizing MAb was longer (CHIKV E1-K61T,
5.8 days; CHIKV E2-D59N, 5.4 days; CHIKV E1-K61T E2-D59N,
6.4 days) than that with CHIKV WT in the absence of MAb. To
TABLE 1 Infection rates of CHIKVs in A. albopictus at days 7, 10, and 14 after infection
Viremic blood meal
Infection rate (no. of infected mosquitoes/total no. in group [%])
at:a
Titer at day 14 p.i.
(log10 TCID50/ml [n])
bDay 7 p.i. Day 10 p.i. Day 14 p.i.
Mock (defibrinated sheep blood) 0/15 (0) 0/13 (0) 0/26 (0) ND
WT 15/16 (94) 22/22 (100) 30/35 (86) 4.99 0.50 (11)
E1-K61T 36/41 (88) 14/16 (88) 36/44 (82) 4.65 0.91 (12)
E2-D59N 30/33 (91) 14/15 (93) 40/43 (93) 5.44 0.64 (11)
E1-K61T E2-D59N 34/42 (81) 12/13 (92) 33/44 (75) 5.04 0.90 (11)
a A. albopictus mosquitoes were fed a blood meal of equivalent amounts of WT and the indicated mutant CHIKVs. Mosquitoes were collected at different days postinfection (p.i.),
dissected, and analyzed for viral antigen expression in the abdomen using indirect immunofluorescence microscopy (expressed as rate of infection). None of the values for mutant
viruses were significantly different (P 0.05) from the WT level at any of the days tested, as judged by a Fisher’s exact test.
b Whole mosquitoes were collected at day 14 postinfection and homogenized, and titers of infectious virus were determined on Vero cells. The data are expressed as log10 TCID50/
ml standard deviation, and the number of individual mosquitoes tested per group is indicated in parentheses. ND, not determined.
TABLE 2 Dissemination rates of WT and variant CHIKVs in A.
albopictus at days 7, 10, and 14 after infection
Viremic blood
meal
Dissemination rate (no. of positive mosquitoes/
total no. of mosquitoes [%]) at:a
Day 7 p.i. Day 10 p.i. Day 14 p.i.
WT 10/10 (100) 12/12 (100) 21/21 (100)
E1-K61T 25/25 (100) 11/11 (100) 26/26 (100)
E2-D59N 17/18 (94) 10/10 (100) 29/29 (100)
E1-K61T E2-D59N 23/23 (100) 8/8 (100) 25/25 (100)
a A. albopictus mosquitoes were fed a blood meal of equivalent amounts of WT and
indicated mutant CHIKV. Mosquitoes were collected at different days postinfection
(p.i.), dissected, and analyzed for viral antigen expression in the secondary tissues using
indirect immunofluorescence microscopy.
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evaluate this further, we recovered virus from the muscle of three
independent moribund mice infected with CHIKV WT, CHIKV
E1-K61T, CHIKV E2-D59N, and CHIKV E1-K61T E2-D59N vi-
ruses in the absence or presence of neutralizing antibody treat-
ment and sequenced the E1 and E2 genes directly. We predicted
that highly attenuating mutations in vivo might revert to WT se-
quences in the absence of immune pressure. Despite the slight
differences in virulence reflected by prolongation of the survival
time, the engineered mutations (E1-K61T, E2-D59N, and E1-
K61T E2-D59N) were retained in muscle tissue in the absence or
presence of the respective neutralizing MAb(s), as judged by con-
sensus sequencing (see Fig. S5 in the supplemental material). We
also observed no statistically significant difference in viral burdens
at day 2 after infection for any of themutant viruses relative to the
WTvirus in the serum, spleen, liver,muscle, or brain (Fig. 4E to J).
Thus, the escape mutant viruses were stable and pathogenic in
Ifnar1/mice although there was a slight delay in the kinetics of
lethal infection that did not reflectmajor differences in tissue viral
burden.
As it was unclear why themutant viruses were slightly clinically
attenuated yet stable and replicating to nearly WT virus levels, we
speculated that theremight be an adaptive immune pressure (e.g.,
IgM response) during the early host response which favored re-
tention of the mutant strains. To assess this, we infected Rag1/
C57BL/6 mice, which lack functional B and T cells and do not
produce antibody, with WT or CHIKV E1-K61T E2-D59N virus.
Prior studies had established thatRag1/mice develop persistent
CHIKV infection (31), so these animals also allowed us to follow
the stability of the mutant virus in an immunocompromised
mammalian host over several weeks. At days 14 and 28 after infec-
tion, viremia reached equivalent levels in Rag1/ mice infected
with CHIKVWT and CHIKV E1-K61T E2-D59N (Fig. 4K). Con-
sensus sequencing of the E2-E1 genes from tissues harvested from
Rag1/mice at day 28 revealed no changes to the WT virus and
no evidence of reversion of CHIKV E1-K61T E2-D59N virus de-
spite the many rounds of replication that occurred during the
4-week interval (see Fig. S6 in the supplemental material). Thus,
in the absence of adaptive immune pressure, the mutant CHIKV
E1-K61T E2-D59N replicated to normal levels and was remark-
ably stable.
Phenotype of neutralization escape variants in persistently
infected immunocompetent mice. Models of acute and chronic
FIG 4 Virulence of WT and mutant CHIKV strains in immunocompromised Ifnar1/ or Rag1/mice. (A to D) Six- to eight-week-old Ifnar1/mice were
passively transferred saline or 50g of each antibody, CHK-166 andCHK-152, via an intraperitoneal injection 1 day before infectionwith 10 FFU of CHIKVWT
(A), CHIKV E1-K61T (B), CHIKV E2-D59N (C), or CHIKV E1-K61T E2-D59N (D) virus via a subcutaneous route. The survival curves were constructed from
data of at least two independent experiments with between 7 and 10 mice per group. (E to J) Six week-old Ifnar1/mice were infected with 10 FFU of CHIKV
WT, CHIKV E1-K61T, CHIKV E2-D59N, or CHIKV E1-K61T E2-D59N (DM) virus via a subcutaneous route. At day 2 after infection, serum, spleen, liver,
muscle (right leg), and brain were harvested from individual mice for virus titration by focus-forming assay. The data are the average standard deviation from
4 to 6 mice per group. The differences in viral burden did not attain statistical significance (P 0.1, Mann-Whitney test). (K) Rag1/mice were infected with
103 FFU of CHIKVWT or CHIKV E1-K61T E2-D59N (DM) via a subcutaneous route. Blood samples were obtained from individual animals at days 14 and 28
after infection, and CHIKV RNA was measured by qRT-PCR. No statistically significant differences were observed.









CHIKVWT PBS 0 3.8 0.1 10
CHIKVWT CHK-152 CHK-166 100 21 7
CHIKV E1-K61T PBS 0 4.9 0.1 9
CHIKV E1-K61T CHK-166 0 5.8 0.3 9
CHIKV E2-D59N PBS 0 4.9 0.1 8
CHIKV E2-D59N CHK-152 0 5.4 0.2 9
CHIKV E1-K61T
E2-D59N
PBS 0 5.4 0.2 10
CHIKV E1-K61T
E2-D59N
CHK-152 CHK-166 0 6.4 0.3 10
a Six to 8 week-old Ifnar1/mice were passively transferred PBS or 50 g of CHK-
166, CHK-152, or CHK-166 plus CHK-152 via an intraperitoneal injection 1 day before
infection with 10 FFU of CHIKVWT, CHIKV E1-K61T, CHIKV E2-D59N, or CHIKV
E1-K61T E2-D59N virus via a subcutaneous route.
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joint disease caused by persistent CHIKV infection in immuno-
competent C57BL/6 mice recently have been established (30, 31,
34, 58). Because the time course of disease pathogenesis in If-
nar1/ mice was short, we reasoned that the relative virulence
and propensity for reversion of mutant strains might be revealed
in a persistence infection model. Accordingly, we inoculated
3-week-old WT C57BL/6 mice with 103 FFU of BHK21 cell-de-
rived CHIKV WT, CHIKV E1-K61T, CHIKV E2-D59N, or
CHIKV E1-K61T E2-D59N virus in the left rear footpad. During
the acute phase, we monitored swelling in the ipsilateral foot and
ankle. At days 3 and 7 after inoculation, all three mutant viruses
caused less swelling than the parentWTvirus (2-fold decrease in
size, P 
 0.0001) (Fig. 5A), suggesting a decrease in virulence
during the acute phase. However, analysis of the levels of viral
RNA or infectious virus in the ipsilateral (left) and contralateral
(right) ankles or infectious virus in the serum failed to reveal a
difference in replication levels of the mutant viruses (Fig. 5B and
C), despite their attenuated clinical phenotype. As clinical atten-
uation and genetic stability of theCHIKVE1-K61TE2-D59Nmu-
tant virus also were observed at days 3 and 7 after infection with a
C6/36 cell (P1)-passaged viral stock, it is unlikely that attenuated
minority populations generated in the original BHK21 (P0) virus
stock could explain the phenotype. Because prior studies with
attenuated CHIKV strains containing mutations in the E2 gene
(E2-E79K and E2-G82R) had observed less foot swelling (34) or
greater weight loss (59) that was associated with differences in
inflammatory mediators (36), we measured cytokine and chemo-
kine responses at day 3 after infection in WT mice infected with
CHIKV WT or CHIKV E1-K61T E2-D59N virus. Compared to
infection with CHIKV WT, animals inoculated with CHIKV E1-
K61T E2-D59N produced low serum levels of several proinflam-
matory cytokines and chemokines, including IL-5, IL-12 p40,
MCP-1 (CCL2), and RANTES (CCL5), at day 3 (Fig. 5D to U).
These animals were followed into the persistence phase; at day
28 postinoculation, tissueswere harvested, and qRT-PCRwas per-
formed. In this model, persistent CHIKV RNA and synovitis are
present in joint-associated tissue although clinically apparent in-
flammation has receded (31). At day 28, viral RNA levels in the
contralateral right ankle and left wrist, which reflect both viral
spread and persistence, were similar between theWT and mutant
viruses (Fig. 5V). Sequencing studies of the complete E2-E1 genes
of viral RNA harvested from the right ankle of mice at day 28 after
infection with themutant CHIKV revealed no reversion at the site
of the introduced mutation (see Fig. S7 in the supplemental ma-
terial) nor emergence of a reproducibly selected second site mu-
tation. One exception was a low-frequency G-to-A substitution at
position 10513 in viral RNA from three mice (two of four CHIKV
E2-D59N and one of four CHIKV E1-K61T mice), which results
in a D-to-N coding change in the E1 gene at amino acid 174. The
significance of this change remains unclear as it did not segregate
with one of the twomutant viruses and also was not present in the
animals infected with the double mutant (CHIKV E1-K61T E2-
D59N) virus. Thus, although an attenuated clinical phenotype of
theCHIKVmutant viruses was observed during the acute phase of
infection and disease, in the absence of immune pressure rever-
sion to the WT parental virus failed to occur, and the mutant
viruses showed a similar ability to persist.
Competition studies reveal a fitness advantage of themutant
virus in mice. As a test of the relative stability and fitness of the
doublemutant (CHIKVE1-K61TE2-D59N) escape virus, we per-
formed competition studies in WT C57BL/6 mice. CHIKV WT
andCHIKVE1-K61TE2-D59Nvirusesweremixed in a 5:1, 1:1, or
1:5 FFU ratio and injected in the left rear footpad. As a control, we
compared the genomic RNA-to-FFU ratios of the input viruses.
CHIKV WT and CHIKV E1-K61T E2-D59N viruses had similar
relative levels of genomic RNA per unit of infectious virus (1.04
0.13 and 1.03 0.20 copies of RNA per FFU for CHIKVWT and
CHIKV E1-K61T E2-D59N, respectively). At 28 days after ini-
tial infection, tissue from the right ankle was harvested, and con-
sensus sequencing of the complete E2-E1 genes from viral RNA
was performed. Unexpectedly, in tissue samples from four of four
mice from each of the three cohorts, the mutant virus sequence
(CHIKV E1-K61T E2-D59N) was detected regardless of the input
ratio (see Fig. S8A and B in the supplemental material). In only
one sample, did we observe sequence corresponding to CHIKV
WT, and this was a minority population (Fig. S8C). Thus, the
mutant virus not only was stable but also showed enhanced fitness
as reflected by its dominance 4 weeks later in a tissue distant from
the infection site.
DISCUSSION
NeutralizingMAbs are being explored as a platform for treatment
of acute or chronic CHIKV infections (31, 49, 52, 54, 55). For
CHIKV in particular, where humans are an integral part of the
endemic and epidemic transmission cycles, the rapid emergence
of resistance and transmission of such variants to mosquitoes
could render therapeutic antibodies less effective. Previously, we
identified a pair of neutralizing anti-CHIKVMAbs (CHK-152 and
CHK-166) against the E2 and E1 structural proteins with thera-
peutic efficacy in immunocompetent and immunocompromised
mice (31, 52). CombinationMAb therapy was required as admin-
istration of a single MAb resulted in the selection of dominant
single-mutation escape variants in vitro and in vivo and treatment
failure. In the present study, we initially confirmed the efficacy of
this combination MAb therapy in a nonhuman primate model of
CHIKV infection. Combination CHK-152 and CHK-166 MAb
therapy in rhesus macaques reduced viral infection and spread
and neutralized reservoirs of infectious virus; for reasons that re-
main unclear, viral RNA persisted in the presence ofMAb therapy
although infectious virus was not recovered. At the level of con-
sensus sequencing, escape viruseswere not detected in the residual
viral RNA present in tissues and organs of rhesus macaques. Al-
though the significance of the persistent CHIKV RNA is uncer-
tain, it could reflect populations of cells that actively propagate
viral RNA. Why such cells are not targeted for elimination by
cytolytic T cells or the effector mechanisms of CHK-152 and
CHK-166 (e.g., antibody-dependent cellular cytotoxicity or
phagocytosis), which should recognize the E2 and E1 proteins on
the surface of infected cells, remains an area of future investiga-
tion.
To define the possible significance of neutralization escape, we
engineered themutations (E1-K61T, E2-D59N, and E1-K61T E2-
D59N) into the infectious CHIKV cDNA clone and tested the
infectivity of the recombinant viruses in mosquito cells and A.
albopictus mosquitoes. In cell culture, the recombinant mutant
viruses were stable without apparent attenuation as they grew
equivalently in the presence or absence of antibody pressure. InA.
albopictus mosquitoes, after a blood meal, the mutant viruses
showed levels of midgut and salivary gland infection similar to
those of the WT virus, again with no evidence of reversion at 14
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FIG5 Virulence ofWTandneutralization escape variant viruses inWTC57BL/6mice. Three-week-oldWTC57BL/6micewere infectedwith 103 FFUofCHIKV
WT, CHIKV E1-K61T, CHIKV E2-D59N, or CHIKV E1-K61T E2-D59N virus via a subcutaneous route. (A) At days 3 and 7 after infection, measurements of
joint swelling weremade. Statistically significant differences are indicated (***, P
 0.001). (B and C) At day 3, the ipsilateral (left) and contralateral (right) ankle
to the site of injection were harvested, and virus was titrated by qRT-PCR (B) or plaque assay (C, for serum). (D to U) At day 3 after infection with CHIKVWT
or CHIKV E1-K61T E2-D59N virus, serum was harvested and processed for the indicated cytokines and chemokines. The results are displayed as a scatter plot
from three independent experiments from a total of nine mice. Statistically significant differences are indicated (*, P
 0.05). (V) At day 28, the indicated tissues
were harvested, and yield was analyzed by qRT-PCR. None of the values obtained with the mutant viruses was statistically different from that of the WT virus.
These results were pooled from two independent experiments with a total of 4 to 8 mice per group.
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days, at least in the bulk population. Thus, in cell culture and
mosquitoes, themutant viruses maintained infection and dissem-
ination potential and were not purified, nor did they acquire
compensatory mutations in the structural genes. This finding in
mosquitoes was unexpected because alignment of the E1-K61 and
E2-D59 sequences with 140 different historical and circulating
CHIKV strains had revealed complete conservation of the WT
residues (52). One caveat to our study is that the infection condi-
tions ofA. albopictus in the laboratory differ from those in the field
such that selection bias against certain mutant viruses could still
occur. Natural populations vary widely with respect to vector
competence, and as such there is no one “representative” wild
population. Consequently, although our results apply to colo-
nized mosquitoes infected under laboratory conditions, further
validation with field strains may be required.
We performed analogous selection studies with the engineered
mutant CHIKV strains inmammalian cells and immunocompro-
mised (Ifnar1/) and immunocompetent mice. In Vero cell cul-
ture, no difference in infectionswas observed between theWTand
variant viruses in multistep growth curve analysis. In Ifnar1/
mice, in the absence of MAb pressure, the escape viruses were
stable at the level of consensus sequencing but exhibited mild
clinical attenuation; this was reflected by a longer mean survival
time and occurred regardless of whether MAb pressure was pres-
ent. However, this was not associated with differences in tissue
viral burden among the WT and mutant viruses, at least early
during the course of infection. In immunocompetent C57BL/6
mice, the mutant viruses also showed evidence of clinical attenu-
ation as decreased joint swelling was observed during the acute
phase of infection compared to the parent WT virus; again, this
was not associated with decreased replication in the joint tissues.
Moreover, the mutant viruses were not cleared more rapidly, and
persistent viral RNAwas present at equivalent levels relative to the
WT virus in several tissues at day 28. Consensus sequencing of the
E1 and E2 genes during the persistence stage failed to reveal rever-
sion. Unexpectedly, in direct competition studies inWTmice, the
double mutant (CHIKV-E1-K61T E2-D59N) showed enhanced
fitness as the mutant but not WT virus sequence was detected in
tissue samples from all (12 of 12) mice 4 weeks after infection,
regardless of the starting infection ratio. Although themechanistic
basis for the relative fitness of the double mutant (CHIKV-E1-
K61T E2-D59N) in vivo remains uncertain, amino acid substitu-
tions in a structural protein could impact steps thatmodulate viral
tropism (attachment, entry, or fusion) or assembly. Overall, the
dominant neutralization escape mutants to CHK-152 and CHK-
166 show evidence of disease attenuation in mice although rever-
sion and compromised fitness were not observed in the acute and
persistent phases of infection. Additionally, the magnitude of the
clinical phenotype during the acute phase did not predict the de-
velopment of viral persistence in mice. In humans, while one
study showed that chronic infection and symptoms were associ-
ated with higher viral loads during the acute phase (60), another,
analogous to our findings, found that high viral loads and severity
of acute disease failed to correlate with development of chronic
disease (61). Clearly, the relationship between acute disease sever-
ity, acute viral loads, and chronic disease/infection warrants fur-
ther study.
The retention of replication efficiency in Vero cells suggests
that the mutations in the E1 and E2 proteins do not affect the
fundamental processes of attachment, entry, fusion, or assembly.
So why are the escape viruses clinically attenuated in vivo in both
WT and Ifnar1/mice? Plausible explanations exist. (i) The cel-
lular tropism in vivo (e.g., muscle cells or fibroblasts) is affected by
themutations in E1 and E2 (62).Mutations in the structural genes
could impact infection of one cell type but not another. (ii) The
mutant viruses are preferentially recognized by antibody or T cells
due to slight changes in epitopes, which could impact pathogen-
esis (63). The latter hypothesis seems less likely, given our results
showing sequence stability in Rag1/mice, which lack mature B
and T cell responses. The significance of these results for antibody
therapy in humans remains uncertain. While it is possible that
these escape mutants (E2-D59N, E1-K61T, E2-D59N E1-K61T)
against CHK-152 andCHK-166will be attenuating, species differ-
ences in cellular tropismor immune recognitionmaynot translate
directly in humans.
Although the variant (E1-K61T and E2-D59N) CHIKVs repli-
cated equivalently, they caused reduced disease with delayed ki-
netics compared to the parental virus. The absence of a link be-
tween viral burden in the joint and the clinical phenotype of joint
swelling in the context of infection by CHIKV has been reported.
Ifnar1/ mice inoculated with a candidate vaccine strain of
CHIKV (CHIKV-181/25) failed to cause arthritis despite attaining
titers that were similar to those achieved with disease-causingWT
strains (34, 59). A genetic analysis of CHIKV-181/25 identified
two mutations in the E2 gene (E2-T12I and E2-G82R) that were
associated with decreased footpad swelling and clinical virulence
(59), and the E2-G82R mutation has been demonstrated to pro-
mote heparan sulfate binding (34, 64). Although it remains un-
clear how changes at E1-K61 and E2-D59 altered the clinical phe-
notype, these substitutions affected the early proinflammatory
response. At day 3 after CHIKV-E1-K61T E2-D59N infection,
when tissue swelling was lower, decreased levels of several cyto-
kines and chemokines (IL-5, IL-12 p40, MCP-1, and RANTES)
were detected in the serum. Notably, levels of IL-5, IL-12, and
MCP-1 also were blunted in CD-1 mice infected with clinically
attenuated CHIKV strains encodingmutations in the E2 gene that
promoted heparan sulfate binding (36). Although immune sys-
tem components may contribute to (e.g., IFN-	 [65] or macro-
phages [29], T and B cells [31, 63], and CD4 T cell-major histo-
compatibility complex [MHC] class II interactions [63, 65]) or
limit (e.g., dendritic cell immunoreceptor, or DCIR [66]) joint
swelling after CHIKV infection, the specific steps in pathogenesis
remain to be determined. Detailed immunological and patholog-
ical studies in WT and gene-targeted mice with the E1-K61 and
E2-D59 mutant viruses are planned to further define the mecha-
nistic basis for their attenuated clinical phenotypes.
In bothmosquito cell culture andA. albopictusmosquitoes, the
escape variant viruses retained the ability to replicate and dissem-
inate with kinetics that were essentially identical to those of the
parent WT viruses. Quantitative viral yield analysis in the whole
mosquito also failed to reveal growth defects of the variant viruses.
Moreover, direct sequencing showed no reversion of the mutant
viruses to the parent WT strain in mosquitoes. These data suggest
that if resistant viruses were selected in the course of combination
MAb therapy, the vector host might not purify them. This result,
in theory, might make the combination of CHK-152 and CHK-
166 a less attractive therapy. However, there are some consider-
ations: (i) although single escape mutations readily were selected
during monotherapy with CHK-152 or CHK-166, double muta-
tions were never obtained during combination therapy despite
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extensive passages in vitro or in vivo (52); (ii) it remains possible
that mutant viruses will be more attenuated in humans than in
mice. Although the CHK-152 and CHK-166 escape mutations
(E2-D59 and E1-K61T) were not purified during passage through
mosquitoes, this type of analysis will be useful with other combi-
nations of neutralizing humanized or fully human anti-CHIKV
MAbs to help define targets for clinical development.
In summary, our study confirmed the efficacy of combination
MAb therapy against CHIKV infection in rhesus macaques and
evaluated the significance of possible resistance in mosquito and
mammalian cells, mice, and Aedes albopictus mosquitoes. Al-
though purification and the acquisition of compensatory muta-
tions were not observed, viruses resistant to CHK-152 and/or
CHK-166 were clinically attenuated yet retained fitness in two
different mouse models. Infectivity studies in nonhuman pri-
mates with mutant viruses, coupled with deep-sequencing ap-
proaches, may be needed to resolve the significance of the emer-
gence of neutralization escape variants against CHK-152 and
CHK-166. We suggest that similar studies should be performed
with MAb-based therapeutics against arthropod-borne viruses
that have epidemic cycles between humans and insect vectors.
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